|
Study
|
Dasatinib
|
Nilotinib 600 mg
|
Nilotinib 800 mg
|
Imatinib 400 mg
|
Imatinib 800 mg
|
|---|
|
Complete cytogenic response
|
|
6 months
| | | | | |
|
DASISION
|
73.0%
| | |
59.2%
| |
|
ENESTed
| |
67.0%
|
63.0%
|
44.9%
| |
|
Baccarani et al.
| | | |
50.0%
|
51.9%
|
|
German CML Study IV
| | | |
21.5%
|
33.5%
|
|
Cortes et al. 2010
| | | |
44.6%
|
56.7%
|
|
ISTAHIT
| | | |
19.8%
|
43.8%
|
|
SPIRIT
| | | |
50.0%
|
69.0%
|
|
12 months
| | | | | |
|
DASISION study group
|
83.4%
| | |
71.5%
| |
|
ENESTed study group
| |
80.1%
|
77.9%
|
65.0%
| |
|
Baccarani et al. (2009)
| | | |
58.3%
|
63.9%
|
|
German CML Study IV
| | | |
49.8%
|
63.2%
|
|
Cortes et al. 2010
| | | |
65.6%
|
69.9%
|
|
S0325 Intergroup Trial
|
82.0%
| | |
69.0%
| |
|
SPIRIT
| | | |
58.0%
|
65.0%
|
|
18 months
| | | | | |
|
Dasatinib Study Group
|
88.6%
| | | | |
|
DASISION study group
|
78.0%
| | |
70.0%
| |
|
ENESTed study group
| |
85.0%
|
82.0%
|
74.0%
| |
|
German CML Study IV
| | | |
66.6%
|
73.8%
|
|
Major Molecular response
|
|
12 months
| | | | | |
|
Bacarrani et al. (2009)
| | | |
33.3%
|
39.8%
|
|
DASISION study group
|
45.9%
| | |
28.1%
| |
|
ENESTed Study group
| |
44.0%
|
43.1%
|
21.9%
| |
|
German CML Study IV
| | | |
30.8%
|
54.8%
|
|
Cortes et al. 2010
| | | |
40.1%
|
46.4%
|
|
SPIRIT
| | | |
38.0%
|
49.0%
|
|
S0325 Intergroup Trial
|
59.0%
| | |
43.0%
| |
